Trial Profile

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 03 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nogapendekin alfa inbakicept (Primary) ; Pembrolizumab (Primary) ; Cobalamin; Dexamethasone; Docetaxel; Folic acid; Gemcitabine; Pemetrexed; Ramucirumab
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms A Lung-MAP Treatment Trial; Lung-MAP trial

04 Jun 2024 According to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology, Accrual in the ARC and PRC were closed at the IA1.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
21 Apr 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com